Ireland’s industrial landscape is defined by twin engines of high-tech growth: the digital infrastructure sector, represented by global data center campuses, and the life sciences sector, comprising world-leading pharmaceutical and medical device manufacturing. However, as both industries expand rapidly, they are increasingly running up against the physical limits of the island's water, power, and regulatory infrastructure. Recent figures showing that data centers consumed nearly one billion liters of water last year have sparked intense debate. Yet, empirical data reveals that another pillar of Ireland's economy—the biopharmaceutical sector—consumes far more. This resource tension, combined with strict power grid limits, is driving a noticeable shift in new construction toward continental Europe and the United States.
Water Usage in Context: Data Centers vs. Life Sciences
Public scrutiny surrounding the environmental footprint of technology infrastructure in Ireland has intensified. According to reporting and utility data, Ireland's largest data centers consumed approximately one billion liters of water from the public supply in a single year, with cumulative consumption over the past two years surpassing 1.7 billion liters. To cooling-intensive facilities, water is essential for heat dissipation, particularly during warm summer months when air-cooling systems require evaporative assistance to maintain safe operating temperatures for servers.
While one billion liters is a substantial figure, it represents a fraction of the water required by the life sciences sector. Pharmaceutical manufacturing is inherently water-intensive. Unlike data centers, which use water primarily for auxiliary cooling, biopharmaceutical plants use water as a core raw material, a solvent in chemical formulation, and an agent for high-specification cleaning and sterilization. A single large-scale biologics facility can consume hundreds of millions of liters of water annually. Taken as a whole, Ireland’s pharmaceutical sector consumes multiple billions of liters of water each year—estimated at three to five times the total consumption of the data center industry.
The difference in public and political response to water consumption in these two sectors is largely driven by perception and economic output. The life sciences sector employs over 40,000 people directly in Ireland, generating high-value medical products and massive export revenues. Conversely, data centers, once constructed, are highly automated and employ relatively few staff on-site, leading to public debates over the societal utility of allocating scarce natural resources to digital storage versus life-saving medicines.
To put both industries' water consumption into a wider national perspective, infrastructural inefficiencies remain the largest drain on Irish water resources. Uisce Éireann, the national water utility, reports that approximately 37% of all treated drinking water is lost to leaks in the public distribution network before it ever reaches a customer. This leakage accounts for hundreds of millions of liters daily—vastly exceeding the combined annual water intake of every data center and pharmaceutical facility in the country.
The Power Constraint: Ireland's Grid Capacity Limits
While water is a localized concern, electricity supply has become the primary bottleneck for industrial expansion. Data centers have experienced exponential growth in energy demand, driven by the rise of cloud computing and artificial intelligence. Central Statistics Office (CSO) figures show that data centers consumed 21% of Ireland’s total metered electricity in 2023, exceeding the total consumption of all rural dwellings combined and matching the consumption of all urban dwellings.
This rapid increase has strained the national electricity grid, prompting EirGrid, the state-owned transmission system operator, to enforce a de facto moratorium on new data center connections in the Greater Dublin Area. Under these directions, applications for new data center connections are assessed against strict criteria, including the developer's ability to generate their own on-site backup power or co-locate with renewable energy generation.
These grid constraints are spilling over into the life sciences sector. Modern biopharmaceutical manufacturing suites—particularly those producing complex biologics and advanced therapeutics—require continuous, uninterrupted power to maintain sterile environments and run precise bioreactors. A single unplanned power disruption can ruin entire batches of medicine, costing millions of euros and disrupting global drug supply chains. As a result, pharmaceutical companies seeking to expand their manufacturing capacity in Ireland are facing longer lead times for grid connections and increased pressure to invest in costly on-site generation, such as natural gas turbines or large-scale battery storage.
The Geographic Shift: Capital Re-allocating Globally
Faced with grid bottlenecks, planning delays, and resource constraints in Ireland, multinational corporations are actively diversifying their infrastructure footprints. The construction of new data centers and pharmaceutical facilities is increasingly shifting to alternative jurisdictions across Europe and the United States.
In the data center industry, developers are targeting secondary markets in Europe—often referred to as "FLAP-D" alternatives (Frankfurt, London, Amsterdam, Paris, Dublin)—as well as emerging regions in the United States (such as Texas, the Carolinas, and Pennsylvania) and Southeast Asia (such as Johor and Batam). These locations offer larger land packages, faster planning approvals, and more direct access to scalable power grids, allowing operators to build the massive, AI-ready facilities that are currently difficult to commission in Ireland.
A similar trend is visible in the pharmaceutical sector. While Ireland remains a premier global hub for established manufacturing, new capital investments for advanced biologics, cell and gene therapies, and active pharmaceutical ingredient (API) synthesis are increasingly being drawn to continental Europe (including Germany, Switzerland, and Belgium) and the US. These jurisdictions are competing aggressively by offering streamlined regulatory approvals, fast-track planning pathways, and robust infrastructure guarantees to capture the next wave of high-value life sciences manufacturing.
A Balanced Pathway Forward
To retain its standing as a top destination for foreign direct investment (FDI) while protecting its environment and utility infrastructure, Ireland is adapting its industrial policies. The focus is shifting toward "decoupling" growth from resource consumption through several strategic initiatives:
- Transition to Closed-Loop Systems: Modern data centers are increasingly utilizing dry cooling systems that recycle water in a closed loop, reducing their net water consumption to near zero, albeit at a slightly higher electricity cost.
- District Heating Integration: New data centers are being designed to export their waste heat to nearby municipal heating networks, providing low-carbon heating to local communities and improving overall energy efficiency.
- On-Site Renewable Microgrids: Industrial parks hosting both data centers and pharmaceutical plants are exploring localized microgrids, combining solar arrays, wind turbines, and hydrogen-ready turbines to reduce reliance on the national grid.
By enforcing stricter sustainability criteria and encouraging co-location, Ireland aims to transition from a model of rapid, resource-intensive expansion to one of high-efficiency, sustainable development. Navigating this transition will determine whether the nation can remain a key player in the global digital and scientific economies in the decades to come.
